Non-Small Cell Lung Cancer (NSCLC)

A panel of oncology experts examine the role of consolidation immunotherapy in patients receiving concurrent chemoradiotherapy for unresectable Stage-III NSCLC, discussing 5-year survival outcomes from the PACIFIC trial, the impact on institutional treatment approaches, criteria for selecting patients for consolidation durvalumab, the significance of baseline scans, as well as exploring real-world evidence on consolidation durvalumab.

Krishna Reddy, MD, PhD, explores the roles of sequential and concurrent chemoradiotherapy (sCRT and cCRT) in patients with unresectable stage III NSCLC, delving into considerations for selecting between the two approaches and examining potential variations in treatment based on factors such as age, performance status (PS), or comorbidities.

The FDA will review the supplemental biologics license application for alectinib based on data from the phase 3 ALINA study.

Expanding or updating coverage with Medicaid may lead to positive health outcomes among patients with non–small cell lung cancer following surgery, according to Leticia Nogueira, PhD, MPH.

Gregory Gan, MD, briefly outlines the available treatment strategies for stage III unresectable NSCLC, and Alykhan Nagji, MD explores the characterization of patients with unresectable stage III NSCLC, underscoring the crucial role of accurate staging in guiding treatment decisions.

Oncology experts from the University of Kansas discuss treatment strategies for both resectable and unresectable non-small cell lung cancer (NSCLC) following progression on adjuvant immunotherapy, providing valuable insights into navigating the challenges posed by this evolving clinical scenario.

Treating patients with NSCLC with stereotactic ablative radiotherapy and chemotherapy reduces toxicity, according to a study conducted by UCLA.

Findings from the phase 1b/3 IMscin001 study support the European Commission’s approval of subcutaneous atezolizumab as a treatment for lung cancer and other disease types.

Data from the phase 3 LUNAR trial support the use of tumor treating fields in patients with non–small cell lung cancer.

Investigators are assessing avutometinib in combination with sotorasib as a treatment for those with KRAS G12C–mutated non–small cell lung cancer in the phase 1/2 RAMP-203 study.

Investigators also report that patritumab deruxtecan is well tolerated in those with EGFR-mutant non–small cell lung cancer in the HERTHENA-Lung01 study.

Vinay Raja, MD, explores the crucial role of adjuvant immunotherapy in resectable stage III NSCLC, providing insights into patient selection criteria, considerations for choosing among available treatment options, and the impact of recent trial data updates on informing treatment decisions in this evolving therapeutic landscape.

Oncology experts from the University of Kansas discuss the evolving role of neoadjuvant/perioperative immunotherapy in resectable stage-III NSCLC, analyzing recent trial data and addressing the nuanced factors that inform their decisions between neoadjuvant and perioperative treatments in clinical practice.

Alykhan Nagji, MD, provides an overview of the institutional approach to determining eligibility for surgical resection, delving into the pivotal role of the multidisciplinary tumor board in the decision-making process and exploring the crucial factors that must be considered when evaluating resectability.

Findings from a randomized trial highlight that treatment with mirtazapine may lead to an improvement in health-related quality of life among those with advanced non–small cell lung cancer and anorexia.

Adding adaptive radiation to chemotherapy may offer a novel approach to treating patients with advanced non–small cell lung cancer, according to Michael Steinberg, MD.

Results from the phase 2 KRYSTAL-1 trial led to the approval of adagrasib for patients with KRAS G12C–mutated non–small cell lung cancer by the European Commission.

Narjust Florez, MD, discusses the complexities of treating KRAS mutations in NSCLC, including the challenges of commutations affecting immunotherapy response, the need for prolonged progression-free survival with KRAS inhibitors, dosage considerations, and highlights ongoing unmet needs and future research directions.

Patients with non–small cell lung cancer who already received LN-145 in the phase 2 IOV-LUN-202 trial will be followed per trial protocol following the FDA’s clinical hold.

A review from the FDA confirms the dose comparison post-marketing requirement that was detailed at the time of sotorasib’s accelerated approval for those with KRAS G12C–mutated non–small cell lung cancer.

Narjust Florez, MD, emphasizes the importance of treating CNS metastases in KRAS G12C mutated NSCLC, highlighting the promising but limited data on adagrasib’s CNS penetrance and intracranial response, as shown in the KRystal-1b study, making it a preferred option for patients with CNS metastases despite its associated side effects.

Dr Narjust Florez discusses the higher incidence of hepatotoxicity with sotorasib as shown in real-world data, and suggests adagrasib as a preferable option for patients with pre-existing liver dysfunction or inflammation, highlighting the need to consider patient history and liver function when choosing KRAS inhibitors.

The application for amivantamab and lazertinib for locally advanced or metastatic non–small cell lung cancer is supported by data from the phase 3 MARIPOSA trial.

“KRAS is probably the most exciting area in clinical trials right now, not only in thoracic oncology but also pancreatic and colorectal cancer, where we’ve seen a lot of combination therapies. My view is the small molecule inhibitors are the base, not the ceiling.”

During the 2023 European Society of Medical Oncology, experts in the field of lung cancer convened to discuss the use of biomarker testing and updated trial results that were presented.